MDPI and ACS Style
Dzinamarira, T.; Almehmadi, M.; Alsaiari, A.A.; Allahyani, M.; Aljuaid, A.; Alsharif, A.; Khan, A.; Kamal, M.; Rabaan, A.A.; Alfaraj, A.H.;
et al. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina 2023, 59, 1041.
https://doi.org/10.3390/medicina59061041
AMA Style
Dzinamarira T, Almehmadi M, Alsaiari AA, Allahyani M, Aljuaid A, Alsharif A, Khan A, Kamal M, Rabaan AA, Alfaraj AH,
et al. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina. 2023; 59(6):1041.
https://doi.org/10.3390/medicina59061041
Chicago/Turabian Style
Dzinamarira, Tafadzwa, Mazen Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A. Rabaan, Amal H. Alfaraj,
and et al. 2023. "Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection" Medicina 59, no. 6: 1041.
https://doi.org/10.3390/medicina59061041